Tyrosine kinase inhibitors, including pazopanib, sunitinib, cabozantinib, and lenvatinib, hold the largest share by blocking VEGFR signalling in major cancer types . https://www.datamintelligence.com/research-report/vascular-endothelial-growth-factor-receptor-inhibitors-market